10X Genomics Debt
| TXG Stock | USD 15.08 0.24 1.62% |
10X Genomics holds a debt-to-equity ratio of 0.126. . 10X Genomics' financial risk is the risk to 10X Genomics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
10X Genomics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. 10X Genomics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps 10X Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect 10X Genomics' stakeholders.
For most companies, including 10X Genomics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for 10X Genomics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, 10X Genomics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that 10X Genomics' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which 10X Genomics is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of 10X Genomics to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, 10X Genomics is said to be less leveraged. If creditors hold a majority of 10X Genomics' assets, the Company is said to be highly leveraged.
10X |
10X Genomics Bond Ratings
10X Genomics financial ratings play a critical role in determining how much 10X Genomics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for 10X Genomics' borrowing costs.| Piotroski F Score | 4 | Poor | View |
| Beneish M Score | (14.73) | Unlikely Manipulator | View |
10X Genomics Debt to Cash Allocation
Many companies such as 10X Genomics, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
10X Genomics has 95.37 M in debt with debt to equity (D/E) ratio of 0.13, which may show that the company is not taking advantage of profits from borrowing. 10X Genomics has a current ratio of 5.54, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for 10X to invest in growth at high rates of return. 10X Genomics Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the 10X Genomics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of 10X Genomics, which in turn will lower the firm's financial flexibility.10X Genomics Corporate Bonds Issued
Most 10X bonds can be classified according to their maturity, which is the date when 10X Genomics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understaning 10X Genomics Use of Financial Leverage
10X Genomics' financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures 10X Genomics' total debt position, including all outstanding debt obligations, and compares it with 10X Genomics' equity. Financial leverage can amplify the potential profits to 10X Genomics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if 10X Genomics is unable to cover its debt costs.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California. 10X Genomics operates under Health Information Services classification in the United States and is traded on NASDAQ Exchange. It employs 12 people. Please read more on our technical analysis page.
Currently Active Assets on Macroaxis
When determining whether 10X Genomics is a strong investment it is important to analyze 10X Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 10X Genomics' future performance. For an informed investment choice regarding 10X Stock, refer to the following important reports:Check out the analysis of 10X Genomics Fundamentals Over Time. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.